Amicus Therapeutics Files 8-K on Financials
Ticker: FOLD · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | 8-K |
| Filed Date | Aug 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: AMTX
TL;DR
AMTX filed an 8-K, check their latest financials.
AI Summary
Amicus Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's performance. The principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
Why It Matters
This filing provides investors with crucial, up-to-date information on Amicus Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain new material events or risks.
Key Players & Entities
- Amicus Therapeutics, Inc. (company) — Registrant
- August 8, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-33497 (identifier) — Commission File Number
- 71-0869350 (identifier) — I.R.S. Employer Identification No.
- 47 Hulfish Street, Princeton, New Jersey 08542 (address) — Principal Executive Offices
- 609 - 662-2000 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Amicus Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on August 8, 2024.
Where are Amicus Therapeutics, Inc.'s principal executive offices located?
Amicus Therapeutics, Inc.'s principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
What is the Commission File Number for Amicus Therapeutics, Inc.?
The Commission File Number for Amicus Therapeutics, Inc. is 001-33497.
In which state was Amicus Therapeutics, Inc. incorporated?
Amicus Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-08-08 07:01:31
Key Financial Figures
- $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar
Filing Documents
- tm2421146d1_8k.htm (8-K) — 26KB
- tm2421146d1_ex99-1.htm (EX-99.1) — 169KB
- tm2421146d1_ex99-2.htm (EX-99.2) — 33KB
- tm2421146d1_ex99-1img001.jpg (GRAPHIC) — 7KB
- tm2421146d1_ex99-2img001.jpg (GRAPHIC) — 325KB
- tm2421146d1_ex99-2img002.jpg (GRAPHIC) — 685KB
- tm2421146d1_ex99-2img003.jpg (GRAPHIC) — 288KB
- tm2421146d1_ex99-2img004.jpg (GRAPHIC) — 232KB
- tm2421146d1_ex99-2img005.jpg (GRAPHIC) — 214KB
- tm2421146d1_ex99-2img006.jpg (GRAPHIC) — 282KB
- tm2421146d1_ex99-2img007.jpg (GRAPHIC) — 218KB
- tm2421146d1_ex99-2img008.jpg (GRAPHIC) — 327KB
- tm2421146d1_ex99-2img009.jpg (GRAPHIC) — 191KB
- tm2421146d1_ex99-2img010.jpg (GRAPHIC) — 202KB
- tm2421146d1_ex99-2img011.jpg (GRAPHIC) — 231KB
- tm2421146d1_ex99-2img012.jpg (GRAPHIC) — 326KB
- tm2421146d1_ex99-2img013.jpg (GRAPHIC) — 237KB
- tm2421146d1_ex99-2img014.jpg (GRAPHIC) — 222KB
- tm2421146d1_ex99-2img015.jpg (GRAPHIC) — 170KB
- tm2421146d1_ex99-2img016.jpg (GRAPHIC) — 236KB
- tm2421146d1_ex99-2img017.jpg (GRAPHIC) — 379KB
- tm2421146d1_ex99-2img018.jpg (GRAPHIC) — 229KB
- tm2421146d1_ex99-2img019.jpg (GRAPHIC) — 130KB
- tm2421146d1_ex99-2img020.jpg (GRAPHIC) — 128KB
- tm2421146d1_ex99-2img021.jpg (GRAPHIC) — 427KB
- tm2421146d1_ex99-2img022.jpg (GRAPHIC) — 182KB
- tm2421146d1_ex99-2img023.jpg (GRAPHIC) — 257KB
- 0001104659-24-086987.txt ( ) — 8860KB
- fold-20240808.xsd (EX-101.SCH) — 3KB
- fold-20240808_lab.xml (EX-101.LAB) — 33KB
- fold-20240808_pre.xml (EX-101.PRE) — 22KB
- tm2421146d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on August 8, 2024 to discuss its second quarter results of operations. A copy of the conference call presentation materials is attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated August 8, 2024 99.2 August 8, 2024 Conference Call Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: August 8, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary